Why oral collagen cannot close a cartilage defect

Many patients diagnosed with a focal cartilage defect are already taking oral collagen supplements — or are wondering whether to start. It is a reasonable instinct: collagen is the dominant structural protein in cartilage, and these supplements are widely available. The evidence does support them for one purpose — easing pain and improving function in diffuse osteoarthritis, where systemic inflammation and general tissue turnover are the relevant targets.

A focal chondral lesion is a different problem. It is a physical void in the joint surface: a gap where the cartilage layer has been lost. Closing that gap requires something physically placed within it. Oral collagen is digested into small peptides, absorbed across the gut wall, and enters systemic circulation — but articular cartilage has no blood supply. There is no vascular conduit through which circulating peptides could reach a focal defect, let alone fill it.

This is not a question of dosage or formulation. It is a question of biological route. A ChondroFiller injection delivers a collagen scaffold directly into the defect site; oral supplementation operates at a systemic level that cartilage's avascular biology places beyond reach.

What makes a focal cartilage defect different from general wear

Think of the difference between a road whose surface has roughened evenly over years and one with a discrete pothole: the first needs resurfacing; the second needs the void filled. A focal cartilage defect is the pothole — a discrete, full- or partial-thickness loss of the cartilage layer at a specific point on the joint surface, creating a mechanically vulnerable gap in otherwise intact tissue.

Articular cartilage is avascular and aneural: it contains no blood vessels and no nerves. Those two absences define the tissue's repair biology. Without a blood supply, there is no inflammatory cascade — the tightly choreographed sequence of bleeding, clotting, and cell recruitment that allows skin or bone to begin healing within hours of injury. The joint surface cannot initiate that response. Left alone, a focal defect either fills gradually with fibrocartilage — a weaker, disorganised tissue that offers poor mechanical performance — or it enlarges as unprotected bone beneath takes cumulative load.

Adequate focal repair requires three things to happen simultaneously at the defect site. First, the void must be physically occupied to prevent fibrocartilage ingrowth and shield the underlying bone. Second, progenitor cells must be held in place long enough to receive the local signals that direct them towards a cartilage-like fate. Third, the repair tissue must integrate mechanically with the surrounding cartilage edges — a seamless junction that can share load without delaminating under movement.

None of those three requirements can be met by a substance that arrives via the bloodstream.

How oral collagen supplements work and where they reach their ceiling

Oral collagen supplements have a genuine, well-documented effect — and the ceiling on that effect is mechanistic, not a product failing.

Two forms dominate the market. Hydrolysed collagen is broken down during digestion into small peptides — principally Pro-Hyp and Hyp-Gly — that are absorbed across the gut wall and enter the bloodstream, where they appear to act as a systemic anabolic signal: influencing how fibroblasts manage collagen production (by upregulating genes such as COL1A1 and COL3A1, which govern collagen synthesis) and reducing the enzymes that break existing collagen down. Undenatured type II collagen works through an entirely different route — oral tolerance — in which small amounts of intact collagen protein train the immune system to dampen its inflammatory response in joints, rather than stimulating any structural repair.

Both effects are real. A systematic scoping review by Honvo and colleagues (2020), covering 41 studies including 25 clinical trials, found that every clinical trial in the oral collagen literature reported beneficial effects on OA symptoms. A well-designed randomised trial of undenatured type II collagen (191 participants, 180 days) confirmed significant WOMAC reductions in pain, stiffness, and physical function versus both placebo and glucosamine/chondroitin.

What no trial measured — because oral collagen is not designed for it — is structural repair of a focal chondral lesion. No enrolled population had isolated focal defects, and no study included structural endpoints such as MRI defect fill or histological tissue quality.

The three focal-repair requirements from the previous section — void occupancy, local cell retention, and mechanical edge-integration — are physical and site-specific. A peptide signal arriving via the bloodstream addresses none of them, regardless of dose or formulation.

How the ChondroFiller injection addresses each repair requirement directly

Void occupancy

Delivered as an ultrasound-guided outpatient injection at the London Cartilage Clinic, ChondroFiller Liquid is a CE-marked injectable Type I collagen hydrogel that polymerises at body temperature within 3–5 minutes. The liquid conforms precisely to the geometry of the defect before setting — filling the void rather than approximating it — providing the physical barrier the site requires to prevent fibrocartilage ingrowth from the outset.

The collagen is produced by a non-enzymatic, weak-acid extraction process that preserves telopeptides intact — the molecular end-caps that govern native fibril cross-linking. Conventional industrial collagen uses pepsin, which cleaves these regions, impairing the material's capacity for physiological self-assembly. Retaining the telopeptides allows ChondroFiller to cross-link as it would in living tissue, producing a structurally coherent lattice rather than a loosely organised gel.

Cell retention

Once set, the scaffold's open porous architecture acts as a chemotactic matrix — recruiting progenitor cells from the adjacent bone marrow and synovial lining without any ex vivo cell preparation or expansion. This is acellular matrix-induced chondrogenesis: the patient's own cells migrate into a framework already positioned inside the defect, held in place rather than dispersed into the joint space.

An ex vivo osteochondral model published in 2025 quantified this effect directly: ChondroFiller-treated 4 mm full-thickness defects showed a 2.4-fold increase in DNA content by day 14 compared with untreated controls, confirming active cellular infiltration into the scaffold.

Mechanical integration

As recruited cells lay down new matrix, repair tissue forms at the defect edges and progressively integrates with surrounding cartilage. One qualification applies at the early stage: biomechanical testing shows that freshly applied ChondroFiller does not reduce stress on opposing cartilage under cyclic loading. This is a characteristic of the scaffold's initial mechanical state, and it directly informs post-injection management — specifically, the recommendation to avoid full weight-bearing until stable integration is achieved.

What the clinical evidence shows for structural repair

Published outcome data across multiple joints and clinical settings point consistently in the same direction — and the endpoints that matter here are structural, not symptomatic.

In the knee, IKDC scores in published series improve by approximately 30 points at 12 months; MRI-based MOCART scores fall in the 70–87 range, indicating well-integrated repair tissue confirmed by imaging rather than patient-reported pain alone. A randomised trial comparing the ChondroFiller injection with microfracture found equivalent functional gains at 3, 6, and 12 months, with MRI demonstrating good defect fill, edge integration from the outset, and progressive tissue maturation — and no adverse events in either arm. Across more than 20,000 implantations performed over ten years, the complaint rate is approximately 0.06%.

The picture holds in other joints. A hip cohort followed for up to five years showed 17 of 21 patients achieving good or excellent outcomes. A 2025 wrist study (Demmer et al., n=25) reported Outerbridge grade 1.5 versus 3.0 (p=0.006) and ICRS grade 1 versus 3 (p=0.002) in favour of ChondroFiller-treated defects over untreated controls — grades assigned arthroscopically, not inferred from symptoms.

The contrast with oral collagen evidence is one of endpoint type. The undenatured type II collagen RCT cited earlier, and the broader body of oral collagen literature reviewed by Honvo (2020), measure WOMAC pain subscales, VAS scores, and physical function — all symptom endpoints. No oral collagen trial has enrolled a focal defect population, and none has used MOCART scoring, Outerbridge grading, or histological tissue quality as primary endpoints. This is not a criticism of those trials; they were designed to measure what oral collagen can plausibly affect.

Two honest caveats apply. Controlled follow-up beyond five years remains limited for ChondroFiller, so longer-term durability data have yet to mature. And no head-to-head randomised trial compares ChondroFiller with oral collagen supplementation — not because such a trial has not been done, but because comparing a local structural scaffold with a systemic anabolic signal would conflate mechanistically unrelated targets.

Who this applies to and how to get assessed in London

The clinical category matters before anything else. ChondroFiller injection is indicated for focal chondral or osteochondral defects — a discrete, MRI-confirmed lesion in an otherwise viable joint — rather than diffuse osteoarthritis affecting a broad joint surface. Patients currently using oral collagen for generalised joint symptoms may be managing a different problem entirely, and the evidence reviewed here applies to each accordingly.

Typical candidates for ChondroFiller injection have a confirmed focal lesion on MRI and persistent symptoms that have not resolved with conservative management. Defect size, joint loading, and individual anatomy all affect suitability — a clinical assessment determines these, not the imaging alone.

In the UK, ChondroFiller injection is delivered at the London Cartilage Clinic on Harley Street, the UK certified centre for the treatment, as an outpatient ultrasound-guided procedure. Professor Paul Y. F. Lee leads that clinical service. Book an assessment at londoncartilage.com.

Oral collagen supplementation and ChondroFiller injection are not competing answers to the same question — they operate at different levels of the problem. Continuing a supplement while a structural defect is addressed by a scaffold is reasonable; substituting one for the other is not. The most useful question to bring to assessment is not which product to take, but whether the damage is focal or diffuse — because that distinction, more than any supplement or scaffold claim, determines what kind of repair is biologically possible.

1. [1] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Efficacy of undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: multicenter RCT. (2015). https://doi.org/10.1186/s12937-016-0130-8 https://doi.org/10.1186/s12937-016-0130-8
3. [3] Hyaline cartilage. https://en.wikipedia.org/?curid=1130627 https://en.wikipedia.org/?curid=1130627
4. [4] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
5. [5] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
6. [6] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
7. [7] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
8. [8] Bioactive Collagen Peptides and Fibroblast-Mediated Matrix Regeneration: From Peptide Absorption to Tissue Remodeling. (2025). https://doi.org/10.21486/recreation.2025.15.4.1 https://doi.org/10.21486/recreation.2025.15.4.1